Search research articles
Contact Us
Filters
Showing results (191-200 of 282) with videos related to
Page
of 29
Sort By:
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
June 8, 2023
Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial
Samuel Tremblay, Mofarej Alhogbani, Andrew Weickhardt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 17, 2025
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024
Ursula M Vogl, Sara Merler, Antonio Angrisani, et al.
BJU International
|
May 24, 2021
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)
Louise Emmett, Shalini Subramaniam, Anthony M Joshua, et al.
BJU International
|
August 21, 2023
The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy
Matthew J Roberts, Ciara Conduit, Ian D Davis, et al.
European Radiology
|
November 7, 2013
Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma
Joe H Chang, Daryl Lim Joon, Sze Ting Lee, et al.
JCO Oncology Practice
|
June 16, 2023
Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations
Ciara Conduit, Jeremy Lewin, Andrew Weickhardt, et al.
The Lancet. Oncology
|
October 19, 2022
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James P Buteau, Andrew J Martin, Louise Emmett, et al.
Plos One
|
September 13, 2012
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen
Rona Y Zhao, Nicole A Mifsud, Kun Xiao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 15, 2006
Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients
Ian D Davis, Qiyuan Chen, Leone Morris, et al.
European Urology Focus
|
May 20, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer
Edmond M Kwan, Heidi Fettke, Maria M Docanto, et al.
Page
of 29
Search research articles
Search
Showing results (191-200 of 282) with videos related to
Sort By:
Page
of 29
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
June 8, 2023
Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial
Samuel Tremblay, Mofarej Alhogbani, Andrew Weickhardt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 17, 2025
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024
Ursula M Vogl, Sara Merler, Antonio Angrisani, et al.
BJU International
|
May 24, 2021
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)
Louise Emmett, Shalini Subramaniam, Anthony M Joshua, et al.
BJU International
|
August 21, 2023
The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy
Matthew J Roberts, Ciara Conduit, Ian D Davis, et al.
European Radiology
|
November 7, 2013
Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma
Joe H Chang, Daryl Lim Joon, Sze Ting Lee, et al.
JCO Oncology Practice
|
June 16, 2023
Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations
Ciara Conduit, Jeremy Lewin, Andrew Weickhardt, et al.
The Lancet. Oncology
|
October 19, 2022
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James P Buteau, Andrew J Martin, Louise Emmett, et al.
Plos One
|
September 13, 2012
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen
Rona Y Zhao, Nicole A Mifsud, Kun Xiao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 15, 2006
Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients
Ian D Davis, Qiyuan Chen, Leone Morris, et al.
European Urology Focus
|
May 20, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer
Edmond M Kwan, Heidi Fettke, Maria M Docanto, et al.
Page
of 29